(Q44452168)

3 December 2017

title

Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia (English)

1 reference

3 December 2017

1 reference

He XY

1

1 reference

3 December 2017

Pohlman B

2

1 reference

3 December 2017

Lichtin A

3

1 reference

3 December 2017

Rybicki L

4

1 reference

3 December 2017

Kalaycio M

5

1 reference

3 December 2017

publication date

1 June 2003

1 reference

3 December 2017

1 reference

3 December 2017

volume

17

1 reference

3 December 2017

issue

6

1 reference

3 December 2017

page(s)

1078-1084

1 reference

3 December 2017

cites work

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

Tailoring the treatment of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

Timed sequential chemotherapy for advanced acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

Timed sequential chemotherapy with concomitant granulocyte colony-stimulating factor for high-risk acute myelogenous leukemia: a single arm clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

Current status and perspectives of therapy for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

Cytogenetic subgroups in acute myeloid leukemia differ in proliferative activity and response to GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

Long chemotherapy-free remissions after single-cycle timed-sequential chemotherapy for acute myelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

7 January 2021

Patients with secondary acute myelocytic leukemia (AML) receiving "timed" sequential chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

7 January 2021

Effects of GM-CSF on Ki67 expression and cell cycle traverse in acute myelogenous leukemia specimens and cell lines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

7 January 2021

Haemopoietic growth factors, the cell cycle of acute myeloblastic leukaemia progenitors and sensitivity to cytosine arabinoside

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

7 January 2021

Recombinant GM-CSF modulates the metabolism of cytosine arabinoside in leukemic cells in bone marrow

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

7 January 2021

Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

7 January 2021

Inpatient management of acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

7 January 2021

Comprehensive criteria for assessing therapy-induced toxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

7 January 2021

Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without gran

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

7 January 2021

Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-cont

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

7 January 2021

Improved survival for patients with acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

7 January 2021

Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

7 January 2021

A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

7 January 2021

Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

7 January 2021

DAE (daunorubicin, Ara-C, and etoposide) and intermediate dose Ara-C for remission induction and consolidation treatment of adult patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402955

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2402955

1 reference

Dimensions Publication ID

3 December 2017

1052036020

0 references

1 reference